Differential effect of mu, delta, and kappa opioid agonists on adenylate cyclase activity

✍ Scribed by Dr. G. M. de Montis; P. Devoto; A. Preti; A. Tagliamonte

• Publisher: John Wiley and Sons
• Year: 1987
• Tongue: English
• Weight: 403 KB
• Volume: 17
• Category: Article
• ISSN: 0360-4012
• DOI: 10.1002/jnr.490170416

✦ Synopsis

D-Ala2, D-Leu5-enkephalin (DADLE) and dynorphinl -13 (Dynl -13) inhibited striatal adenylate cyclase activity, both basal and dopamine-stimulated (DA), in rats and guinea pigs. The K-agonists bremazocine (BRZ), U-50,488 (trans-3,4-dicloro-N-methyl-N-[2-(1-pyrrolidiny1)-cyclohexyl]-benzeneacetamide), and U-69,593 (5a, 7a 8,!3) )-1-oxaspiro (4.5)dec-8yl) benzeneacetamide inhibited only the basal adenylate cyclase activity, and such an effect was restricted to guinea pig striatum, an area known to contain a high density of K-binding sites. Moreover, BRZ was found to antagonize the inhibitory effect of both DADLE and Dynl-13 in rat striatum.